LHLinxin Hua

Linxin Hua

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linxin Hua has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Wang

    College of Optical and Electronic Technology, China Jiliang University, Hangzhou 310018, China

    1 shared publication
  • Hui Fang

    Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China

    1 shared publication
  • Jiawei Zhang

    Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

    1 shared publication
  • Shoujie Chai

    Department of Oncology, Ningbo First Hospital, Ningbo 315010, China

    1 shared publication
  • Shu Li

    Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    1 shared publication
  • Yang Xu

    Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Tubeimoside-2 Triggers Methuosis in Hepatocarcinoma Cells through the MKK4–p38α Axis

    by Yichao Gan, Chen Wang, Yunyun Chen, Linxin Hua, Hui Fang, Shu Li, Shoujie Chai, Yang Xu, Jiawei Zhang, Ying Gu

    Liver cancer, consisting mainly of hepatocellular carcinoma, is the third leading cause of cancer-related mortality worldwide. Despite advances in targeted therapies, these approaches remain insufficient in meeting the pressing clinical demands. Here, we present a novel alternative that calls for a non-apoptotic program to solve the current dilemma. Specifically, we identified that tubeimoside 2 (TBM-2) could induce methuosis in hepatocellular carcinoma cells, a recently recognized mode of cell death characterized by pronounced vacuolization, necrosis-like membrane disruption, and no response to caspase inhibitors. Further proteomic analysis revealed that TBM-2-driven methuosis is facilitated by the hyperactivation of the MKK4–p38α axis and the boosted lipid metabolism, especially cholesterol biosynthesis. Pharmacological interventions targeting either the MKK4–p38α axis or cholesterol biosynthesis effectively suppress TBM-2-induced methuosis, highlighting the pivotal role of these mechanisms in TBM-2-mediated cell death. Moreover, TBM-2 treatment effectively suppressed tumor growth by inducing methuosis in a xenograft mouse model of hepatocellular carcinoma. Taken together, our findings provide compelling evidence of TBM-2’s remarkable tumor-killing effects by inducing methuosis, both in vitro and in vivo. TBM-2 represents a promising avenue for the development of innovative and effective therapies for hepatocellular carcinoma, one that may ultimately offer significant clinical benefits for patients with this devastating disease.